CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of “Hold” from Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have earned an average recommendation of “Hold” from the nineteen research firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $75.63.

Several research firms recently commented on CRSP. Royal Bank of Canada cut their price target on shares of CRISPR Therapeutics from $66.00 to $60.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 6th. Robert W. Baird lifted their target price on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a report on Thursday, May 9th. Wells Fargo & Company lowered their price target on CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating for the company in a report on Thursday, May 9th. Guggenheim restated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Finally, Needham & Company LLC lowered their target price on CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th.

Insiders Place Their Bets

In other news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the sale, the chief operating officer now owns 6,745 shares in the company, valued at approximately $378,327.05. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.10% of the stock is owned by company insiders.

Institutional Trading of CRISPR Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Riggs Asset Managment Co. Inc. grew its position in shares of CRISPR Therapeutics by 66.7% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after acquiring an additional 200 shares in the last quarter. Global Trust Asset Management LLC lifted its stake in CRISPR Therapeutics by 150.0% during the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares during the last quarter. Larson Financial Group LLC boosted its holdings in CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after purchasing an additional 276 shares during the period. NBC Securities Inc. increased its stake in CRISPR Therapeutics by 257.6% during the first quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after purchasing an additional 438 shares during the last quarter. Finally, GPS Wealth Strategies Group LLC raised its holdings in shares of CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after purchasing an additional 307 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Up 0.1 %

NASDAQ:CRSP opened at $47.55 on Friday. CRISPR Therapeutics has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The firm’s 50 day moving average is $53.07 and its two-hundred day moving average is $61.12. The company has a market cap of $4.04 billion, a P/E ratio of -17.48 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The company had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. The company’s revenue was down 99.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.98) EPS. Research analysts forecast that CRISPR Therapeutics will post -5.52 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.